Edison Investment Research - High Peak Royalties (HPR) Initiation: Exposure to oil and gas royalties at a discount

Report

Edison Investment Research

Initiation: Exposure to oil and gas royalties at a discount

High Peak Royalties (HPR) is a growth-focused royalty company, with 20 oil and gas projects in Australia and the Seychelles. It has a strong growth profile driven by the development of new projects and exploration in key areas of activity. The company is supported by an experienced team to grow the royalty portfolio.

17/11/2014 16 EN

Underlying

High Peak Royalties

High Peak Royalties Ltd. High Peak Royalties Limited is engaged in acquisition of royalty and exploration interests in oil and gas assets predominately in Australia and the United States. The Company has royalties on approximately 23 oil and gas projects, including two royalty areas that are in production, located in Australia and the United States. Its portfolio of royalty interests includes PL 171 and ATP 574P; ATP 299P, including the petroleum leases PL29, PL38, PL39, PL52, PL57, PL95, PL169, PL170, PL293, PL294, PL295 and PL298; Pet Gas Field (PL101); Surprise Oil Field (PL6); Longtom Gas Field (VIC/L29 and VIC/P54); WA-314P; WA-315P; EP115NM; PEL512; WA-482-P; EP156, and East Texas, Permian and Texas Gulf Coast Basins in the United States. Its royalty portfolio has access to projects in main oil and gas basins in Australia. Its portfolio spans producing royalties, potential development royalties and exploration royalties.

See profile

AU000000HPR0 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Moody's Investors Service

Moody's downgrades HighPoint's PDR to D-PD on bankruptcy filing

Rating Action: Moody's downgrades HighPoint's PDR to D-PD on bankruptcy filing. Global Credit Research- 15 Mar 2021. New York, March 15, 2021-- Moody's Investors Service, downgraded HighPoint Operating Corporation's Probability of Default Rating to D-PD from C-PD.

EUR 169.25

March 15, 2021 March 15, 2021 5 EN

Moody's Investors Service

HighPoint Operating Corporation: Update following downgrade of bonds to C

Our view of HighPoint reflecting high risk of default, either as a result of our deeming the company's planned bond exchange a distressed exchange or a Chapter 11 filing

EUR 235.08

November 12, 2020 November 12, 2020 8 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

3h / 24m 3h / 24m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

23h / 27m 23h / 27m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

23h / 39m 23h / 39m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN